In February 2021 the phase I/IIa trial (NCT03758664)18 recruited 12 previously-treated CCA patients with FGF/FGFR2 gene aberrations, of whom 1 (8.4%) had a CR, 3 (25.0%) had a PR, and 7 (58.3%) had SD after receiving gunagratinib treatment. The gene discussed is FGFR2; the disease is cholangiocarcinoma.